@prefix ctro: <http://www.semanticweb.org/root/ontologies/2018/6/ctro#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix ratio: <http://www.example.org/ratio-tool#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

ctro:CT_7_0 a ctro:ClinicalTrial,
        owl:NamedIndividual ;
    rdfs:label "Clinical Trial"^^xsd:string ;
    ratio:isRoot true ;
    ctro:described_by_0 ctro:Pub_7_0 ;
    ctro:described_by_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasAdverseEffect_0 ctro:AdverseEffect_7_0 ;
    ctro:hasAdverseEffect_1 ctro:AdverseEffect_7_1 ;
    ctro:hasAdverseEffect_freeindex "2"^^xsd:nonNegativeInteger ;
    ctro:hasArm_0 ctro:Arm_7_0 ;
    ctro:hasArm_1 ctro:Arm_7_1 ;
    ctro:hasArm_freeindex "2"^^xsd:nonNegativeInteger ;
    ctro:hasConclusionComment_0 "To our knowledge, ENSURE-AF is the largest prospective randomised clinical trial of anticoagulation for cardioversion of patients with non-valvular atrial fibrillation. The occurrence of major and CRNM bleeding and thromboembolism was low in the two treatment groups, irrespective of a TEE-guided strategy or whether patients were warfarin naive. Edoxaban is an effective and safe alternative to the best possible conventional treatment with enoxaparin and vitamin K antagonist strategy, and might allow prompt cardioversion to be performed."^^xsd:string ;
    ctro:hasConclusionComment_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDesignGroup_0 ctro:Design_7_0 ;
    ctro:hasDesignGroup_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDiffBetweenGroups_0 ctro:DiffBetweenGroups_7_0 ;
    ctro:hasDiffBetweenGroups_1 ctro:DiffBetweenGroups_7_1 ;
    ctro:hasDiffBetweenGroups_freeindex "2"^^xsd:nonNegativeInteger ;
    ctro:hasEndPoint_0 ctro:EndPoint_7_0 ;
    ctro:hasEndPoint_1 ctro:EndPoint_7_1 ;
    ctro:hasEndPoint_freeindex "4"^^xsd:nonNegativeInteger ;
    ctro:hasObjectiveDescription_0 "Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation and is associated with less bleeding than well controlled warfarin therapy. Few safety data about edoxaban in patients undergoing electrical cardioversion are available."^^xsd:string ;
    ctro:hasObjectiveDescription_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcome_0 ctro:Outcome_7_0 ;
    ctro:hasOutcome_1 ctro:Outcome_7_1 ;
    ctro:hasOutcome_2 ctro:Outcome_7_2 ;
    ctro:hasOutcome_3 ctro:Outcome_7_3 ;
    ctro:hasOutcome_freeindex "4"^^xsd:nonNegativeInteger ;
    ctro:hasPopulation_0 ctro:Population_7_0 ;
    ctro:hasPopulation_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasQualityIndicator_0 ctro:Evidence_7_0 ;
    ctro:hasQualityIndicator_freeindex "1"^^xsd:nonNegativeInteger .

ctro:DiffGroupsMeasureName_7_0 a ctro:DiffGroupsMeasureName,
        owl:NamedIndividual ;
    rdfs:label "Hazard ratio"^^xsd:string ;
    ratio:isCustom true .

ctro:Drug_7_1 a ctro:Drug,
        owl:NamedIndividual ;
    rdfs:label "Enoxaparin–Warfarin"^^xsd:string ;
    ratio:isCustom true .

ctro:EndpointDesc_AF_7_0 a ctro:EndpointDesc_AF,
        owl:NamedIndividual ;
    rdfs:label "Composite"^^xsd:string ;
    ratio:isCustom true .

<http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country> ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:AdverseEffect_7_0 a ctro:AdverseEffect,
        owl:NamedIndividual ;
    rdfs:label "AnyAdverseEvents-edoxaban"^^xsd:string ;
    ctro:hasAEname_0 ctro:EndpointDesc_AF_7_2 ;
    ctro:hasAEname_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasArmAE_0 ctro:Arm_7_0 ;
    ctro:hasArmAE_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberAffectedAE_0 320 ;
    ctro:hasNumberAffectedAE_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasObservedResultAE_0 "30%"^^xsd:string ;
    ctro:hasObservedResultAE_freeindex "1"^^xsd:nonNegativeInteger .

ctro:AdverseEffect_7_1 a ctro:AdverseEffect,
        owl:NamedIndividual ;
    rdfs:label "AnyAdverseEvents-noxaparinWarfarin"^^xsd:string ;
    ctro:hasAEname_0 ctro:EndpointDesc_AF_7_2 ;
    ctro:hasAEname_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasArmAE_0 ctro:Arm_7_1 ;
    ctro:hasArmAE_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberAffectedAE_0 357 ;
    ctro:hasNumberAffectedAE_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasObservedResultAE_0 "33%"^^xsd:string ;
    ctro:hasObservedResultAE_freeindex "1"^^xsd:nonNegativeInteger .

ctro:CTDesign ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:CTDesign_7_0 a ctro:CTDesign,
        owl:NamedIndividual ;
    rdfs:label "Parallel-group"^^xsd:string ;
    ratio:isCustom true .

ctro:ClinicalTrial ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:Country_7_0 a <http://www.bpiresearch.com/BPMO/2004/03/03/cdl/Countries#Country>,
        owl:NamedIndividual ;
    rdfs:label "Europe"^^xsd:string ;
    ratio:isCustom true .

ctro:DesignGroup ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:Design_7_0 a ctro:DesignGroup,
        owl:NamedIndividual ;
    rdfs:label "Design"^^xsd:string ;
    ctro:analysesHealthCondition_0 ctro:AtrialFibrillation ;
    ctro:analysesHealthCondition_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasAnalysisApproach_0 "" ;
    ctro:hasAnalysisApproach_1 ctro:IntentionToTreat ;
    ctro:hasAnalysisApproach_freeindex "2"^^xsd:nonNegativeInteger ;
    ctro:hasCTDesign_0 ctro:OpenLabel ;
    ctro:hasCTDesign_1 ctro:Prospective ;
    ctro:hasCTDesign_2 ctro:Randomized ;
    ctro:hasCTDesign_3 ctro:CTDesign_7_0 ;
    ctro:hasCTDesign_4 "" ;
    ctro:hasCTDesign_5 ctro:Multicenter ;
    ctro:hasCTDesign_6 ctro:Multinational ;
    ctro:hasCTDesign_freeindex "7"^^xsd:nonNegativeInteger ;
    ctro:hasCTduration_0 "" ;
    ctro:hasCTduration_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberPatientsCT_0 "2199"^^xsd:positiveInteger ;
    ctro:hasNumberPatientsCT_freeindex "1"^^xsd:nonNegativeInteger .

ctro:DiffBetweenGroups_7_0 a ctro:DiffBetweenGroups,
        owl:NamedIndividual ;
    rdfs:label "Diff-edoxaban-enoxaparinWarfarin-bleeding"^^xsd:string ;
    ctro:hasConfIntervalDiff_0 "95% (0·55–1·55)"^^rdfs:Literal ;
    ctro:hasConfIntervalDiff_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDiffGroupAbsValue_0 "0.93"^^xsd:float ;
    ctro:hasDiffGroupAbsValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasMeasureName_0 ctro:DiffGroupsMeasureName_7_1 ;
    ctro:hasMeasureName_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcome1_0 ctro:Outcome_7_3 ;
    ctro:hasOutcome1_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcome2_0 ctro:Outcome_7_2 ;
    ctro:hasOutcome2_freeindex "1"^^xsd:nonNegativeInteger .

ctro:DiffBetweenGroups_7_1 a ctro:DiffBetweenGroups,
        owl:NamedIndividual ;
    rdfs:label "Diff-edoxaban-enoxaparinWarfarin-composite"^^xsd:string ;
    ctro:hasConfIntervalDiff_0 "95%"^^rdfs:Literal ;
    ctro:hasConfIntervalDiff_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDiffGroupAbsValue_0 "0.46"^^xsd:float ;
    ctro:hasDiffGroupAbsValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasMeasureName_0 ctro:DiffGroupsMeasureName_7_1 ;
    ctro:hasMeasureName_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcome1_0 ctro:Outcome_7_0 ;
    ctro:hasOutcome1_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcome2_0 ctro:Outcome_7_1 ;
    ctro:hasOutcome2_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Drug_7_0 a ctro:Drug,
        owl:NamedIndividual ;
    rdfs:label "Edoxoban"^^xsd:string ;
    ratio:isCustom true .

ctro:EndpointDesc_AF_7_1 a ctro:EndpointDesc_AF,
        owl:NamedIndividual ;
    rdfs:label "Major and CRNM bleeding"^^xsd:string ;
    ratio:isCustom true .

ctro:EvidenceQuality ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:Evidence_7_0 a ctro:EvidenceQuality,
        owl:NamedIndividual ;
    rdfs:label "Potential Conflicts of Interest"^^xsd:string ;
    ctro:hasConflictInterest_0 "AG has served as a consultant for Bayer, Boehringer Ingelheim (see more in pape)"^^xsd:string ;
    ctro:hasConflictInterest_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasSponsor_0 "Daiichi Sankyo Pharma Development"^^xsd:string ;
    ctro:hasSponsor_1 "aiichi Sankyo Development"^^xsd:string ;
    ctro:hasSponsor_freeindex "2"^^xsd:nonNegativeInteger .

ctro:Interv_7_0 a ctro:Intervention,
        owl:NamedIndividual ;
    rdfs:label "Intervention 1"^^xsd:string ;
    ctro:hasDeliveryMethod_0 ctro:Oral ;
    ctro:hasDeliveryMethod_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDoseUnit_0 ctro:mg ;
    ctro:hasDoseUnit_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDoseValue_0 "60"^^rdfs:Literal ;
    ctro:hasDoseValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDrug_0 ctro:Drug_7_0 ;
    ctro:hasDrug_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasFreqInterval_0 ctro:Daily ;
    ctro:hasFreqInterval_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Intervention_7_1 a ctro:Intervention,
        owl:NamedIndividual ;
    rdfs:label "Intervention1"^^xsd:string ;
    ctro:hasDeliveryMethod_0 ctro:Oral ;
    ctro:hasDeliveryMethod_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDoseValue_0 "Dose adapted to the TEE sttratus: In the TEE-guided stratum: patients in the enoxaparin–warfarin group with INR less than 2·0 started treatment with a minimum of one dose each of enoxaparin and warfarin before cardioversion, and these drugs were continued until INR of 2·0 or greater was obtained. After a therapeutic range was achieved, patients were to discontinue enoxaparin and continue warfarin until end of treatment (day 28 after the procedure). Patients in the enoxaparin–warfarin group with INR above 2·0 at the time of randomisation did not require enoxaparin and were treated with warfarin alone. The dose of warfarin was adjusted to achieve and maintain the therapeutic INR level of 2·0–3·0. INR measurements were conducted once every 2–3 days until the value reached the therapeutic range. In the non-TEE-guided stratum, patients in the enoxaparin–warfarin group with INR of 2·0 or greater at randomisation did not require enoxaparin and received warfarin anticoagulation for a minimum of 21 days from the day of randomisation. Patients with an INR less than 2·0 at randomisation received enoxaparin and daily warfarin until the INR was 2·0 or greater. At that time, enoxaparin was discontinued and warfarin continued for a minimum of 21 days after the day of randomisation. INR measurements were done every 2–3 days until the value reached the therapeutic range and as needed thereafter."^^rdfs:Literal ;
    ctro:hasDoseValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasDrug_0 ctro:Warfarin ;
    ctro:hasDrug_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasFreqInterval_0 "" ;
    ctro:hasFreqInterval_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Population ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:Population_7_0 a ctro:Population,
        owl:NamedIndividual ;
    rdfs:label "Population"^^xsd:string ;
    ctro:hasAvgAge_0 "64"^^xsd:nonNegativeInteger ;
    ctro:hasAvgAge_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasCountry_0 ctro:USA ;
    ctro:hasCountry_1 "" ;
    ctro:hasCountry_2 ctro:Country_7_0 ;
    ctro:hasCountry_freeindex "3"^^xsd:nonNegativeInteger ;
    ctro:hasGender_0 ctro:Female ;
    ctro:hasGender_1 ctro:Male ;
    ctro:hasGender_freeindex "2"^^xsd:nonNegativeInteger ;
    ctro:hasPreconditionDescription_0 "Eligible patients were those with non-valvular atrial fi brillation (of duration no shorter than 48 h and no longer than 12 months) and who were planned for electrical cardioversion and anticoagulation therapy. Patients who were receiving or had received previous anticoagulant or antiplatelet therapies (or both) were eligible, as were patients who had not previously received anticoagulant or antiplatelet therapy."^^xsd:string ;
    ctro:hasPreconditionDescription_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Pub_7_0 a ctro:Publication,
        owl:NamedIndividual ;
    rdfs:label "Publication"^^xsd:string ;
    ctro:hasAuthor_0 "Merino, Michael D Ezekowitz"^^xsd:string ;
    ctro:hasAuthor_1 "Dmitry Zamoryakhin"^^xsd:string ;
    ctro:hasAuthor_2 "Michael Melino"^^xsd:string ;
    ctro:hasAuthor_freeindex "3"^^xsd:nonNegativeInteger ;
    ctro:hasJournal_0 "Lancet"^^xsd:string ;
    ctro:hasJournal_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasPMID_0 "27590218"^^rdfs:Literal ;
    ctro:hasPMID_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasPublicationYear_0 "2016"^^xsd:positiveInteger ;
    ctro:hasPublicationYear_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasTitle_0 "Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial"^^xsd:string ;
    ctro:hasTitle_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Publication ratio:freeindex "1"^^xsd:nonNegativeInteger .

ctro:AdverseEffect ratio:freeindex "2"^^xsd:nonNegativeInteger .

ctro:Arm ratio:freeindex "2"^^xsd:nonNegativeInteger .

ctro:DiffBetweenGroups ratio:freeindex "2"^^xsd:nonNegativeInteger .

ctro:DiffGroupsMeasureName ratio:freeindex "2"^^xsd:nonNegativeInteger .

ctro:DiffGroupsMeasureName_7_1 a ctro:DiffGroupsMeasureName,
        owl:NamedIndividual ;
    rdfs:label "Odd ratio"^^xsd:string ;
    ratio:isCustom true .

ctro:Drug ratio:freeindex "2"^^xsd:nonNegativeInteger .

ctro:EndPoint ratio:freeindex "4"^^xsd:nonNegativeInteger .

ctro:EndpointDesc_AF_7_2 a ctro:EndpointDesc_AF,
        owl:NamedIndividual ;
    rdfs:label "Any Adverse Effect"^^xsd:string ;
    ratio:isCustom true .

ctro:Intervention ratio:freeindex "2"^^xsd:nonNegativeInteger .

ctro:Outcome_7_0 a ctro:Outcome,
        owl:NamedIndividual ;
    rdfs:label "Outcome-edoxaban-composite" ;
    ctro:hasArmOut_0 ctro:Arm_7_0 ;
    ctro:hasArmOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndPointOut_0 ctro:EndPoint_7_0 ;
    ctro:hasEndPointOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasFinalNumberPatients_0 "1095"^^xsd:positiveInteger ;
    ctro:hasFinalNumberPatients_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberAffected_0 5 ;
    ctro:hasNumberAffected_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasObservedResult_0 "<1%"^^xsd:string ;
    ctro:hasObservedResult_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasRelativeValue_0 "" ;
    ctro:hasRelativeValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasTimePoints_0 "overall study period"^^xsd:string ;
    ctro:hasTimePoints_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Outcome_7_1 a ctro:Outcome,
        owl:NamedIndividual ;
    rdfs:label "Outcome-enoxaparin–warfarin-composite"^^xsd:string ;
    ctro:hasArmOut_0 ctro:Arm_7_1 ;
    ctro:hasArmOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndPointOut_0 ctro:EndPoint_7_0 ;
    ctro:hasEndPointOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberAffected_0 11 ;
    ctro:hasNumberAffected_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasRelativeValue_0 "1.0"^^xsd:float ;
    ctro:hasRelativeValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasTimePoints_0 "overall study period"^^xsd:string ;
    ctro:hasTimePoints_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Outcome_7_2 a ctro:Outcome,
        owl:NamedIndividual ;
    rdfs:label "Outcome-enoxaparin–warfarin-bleeding"^^xsd:string ;
    ctro:hasArmOut_0 ctro:Arm_7_1 ;
    ctro:hasArmOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndPointOut_0 ctro:EndPoint_7_1 ;
    ctro:hasEndPointOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasFinalNumberPatients_0 "1082"^^xsd:positiveInteger ;
    ctro:hasFinalNumberPatients_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberAffected_0 11 ;
    ctro:hasNumberAffected_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasRelativeValue_0 "1.0"^^xsd:float ;
    ctro:hasRelativeValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasTimePoints_0 "on-treatment period"^^xsd:string ;
    ctro:hasTimePoints_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Outcome_7_3 a ctro:Outcome,
        owl:NamedIndividual ;
    rdfs:label "Outcome-edoxaban-bleeding" ;
    ctro:hasArmOut_0 ctro:Arm_7_0 ;
    ctro:hasArmOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndPointOut_0 ctro:EndPoint_7_1 ;
    ctro:hasEndPointOut_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasFinalNumberPatients_0 "106"^^xsd:positiveInteger ;
    ctro:hasFinalNumberPatients_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberAffected_0 16 ;
    ctro:hasNumberAffected_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasRelativeValue_0 "1.0"^^xsd:float ;
    ctro:hasRelativeValue_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasTimePoints_0 "on-treatment period"^^xsd:string ;
    ctro:hasTimePoints_freeindex "1"^^xsd:nonNegativeInteger .

ctro:EndPoint_7_0 a ctro:EndPoint,
        owl:NamedIndividual ;
    rdfs:label "Endpoint-composit" ;
    ctro:hasAggregationMethod_0 ctro:Count ;
    ctro:hasAggregationMethod_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndPointDescriptionStr_0 "Efficacy: composite endpoint of stroke, systemic embolic event, myocardial infarction, and cardiovascular mortality."^^xsd:string ;
    ctro:hasEndPointDescriptionStr_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndpointDescription_0 "" ;
    ctro:hasEndpointDescription_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndpointUnit_0 ctro:Number ;
    ctro:hasEndpointUnit_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcomeType_0 "Primary" ;
    ctro:hasOutcomeType_freeindex "1"^^xsd:nonNegativeInteger .

ctro:EndPoint_7_1 a ctro:EndPoint,
        owl:NamedIndividual ;
    rdfs:label "Endpoint-Bleeding"^^xsd:string ;
    ctro:hasAggregationMethod_0 ctro:Count ;
    ctro:hasAggregationMethod_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndPointDescriptionStr_0 "Safety endpoint: Major and clinically relevant non-major (CRNM) bleeding"^^xsd:string ;
    ctro:hasEndPointDescriptionStr_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndpointDescription_0 ctro:EndpointDesc_AF_7_1 ;
    ctro:hasEndpointDescription_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasEndpointUnit_0 ctro:Number ;
    ctro:hasEndpointUnit_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasOutcomeType_0 "Primary" ;
    ctro:hasOutcomeType_freeindex "1"^^xsd:nonNegativeInteger .

ctro:EndpointDesc_AF ratio:freeindex "3"^^xsd:nonNegativeInteger .

ctro:Arm_7_0 a ctro:Arm,
        owl:NamedIndividual ;
    rdfs:label "Arm-edoxaban" ;
    ctro:hasIntervention_0 ctro:Interv_7_0 ;
    ctro:hasIntervention_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberPatientsArm_0 "1095"^^xsd:positiveInteger ;
    ctro:hasNumberPatientsArm_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Arm_7_1 a ctro:Arm,
        owl:NamedIndividual ;
    rdfs:label "Arm-enoxaparin–warfarin" ;
    ctro:hasIntervention_0 ctro:Intervention_7_1 ;
    ctro:hasIntervention_freeindex "1"^^xsd:nonNegativeInteger ;
    ctro:hasNumberPatientsArm_0 "1104"^^xsd:positiveInteger ;
    ctro:hasNumberPatientsArm_freeindex "1"^^xsd:nonNegativeInteger .

ctro:Outcome ratio:freeindex "4"^^xsd:nonNegativeInteger .
